20825-87-0

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential pharmacological properties.
Used in Organic Synthesis:
In the field of organic synthesis, Ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate serves as a valuable building block for the creation of complex organic molecules, contributing to the development of new chemical entities with potential applications in various industries.
Used in Drug Development:
Ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate is used as a precursor in the development of new drugs for various medical conditions, leveraging its anti-inflammatory and analgesic effects. Its potential role in drug development is currently under investigation to determine its full therapeutic potential.
Used in Chemical Research:
In the realm of chemical research, Ethyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate is employed to study the properties of heterocyclic compounds and their interactions with other molecules, which can lead to advancements in understanding chemical reactions and mechanisms.

InChI:InChI=1/C11H12O4/c1-2-13-11(12)8-3-4-9-10(7-8)15-6-5-14-9/h3-4,7H,2,5-6H2,1H3

Upstream product

• 64-17-5 ethanol 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 3943-89-3 Ethyl protocatechuate 
• 106-93-4 ethylene dibromide 

Downstream Products

• 39270-39-8 (2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanol 
• 26309-99-9 6-(chloromethyl)-2,3-dihydrobenzo[b][1,4]dioxine 
• 405902-28-5 C₁₆H₁₃ClN₂O₃ 
• 1362456-10-7 1-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone 
• 349556-48-5 C₁₆H₁₃N₃O₅ 
• 1362456-11-8 1-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(4-methoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone 
• 402611-68-1 C₁₇H₁₆N₂O₄ 
• 1362456-12-9 1-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(p-tolyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone 
• 328130-17-2 C₁₆H₁₂Cl₂N₂O₃ 
• 1362456-18-5 1-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(3-fluorophenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone 
• 1362456-29-8 C₁₆H₁₃FN₂O₃ 
• 1362456-19-6 1-(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(4-fluorophenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone 
• 709635-28-9 C₁₆H₁₃FN₂O₃ 
• 1362456-20-9 4-(3-acetyl-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,3-dihydro-1,3,4-oxadiazol-2-yl)phenyl acetate 

Relevant academic research and scientific papers

Synthesis and antibacterial activity of cinnamaldehyde acylhydrazone with a 1,4-benzodioxan fragment as a novel class of potent ss-Ketoacyl-acyl carrier protein synthase III (FabH) inhibitor

Fatty acid biosynthesis is essential for bacterial survival. ss-Ketoacyl-acyl carrier protein (ACP) synthase III (FabH), is a particularly attractive antibacterial target, since it is central to the initiation of fatty acid biosynthesis. Three series of 2

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents

A series of novel 1,3,4-oxadiazole thioether derivatives (compounds 9-44) were designed and synthesized as potential inhibitors of thymidylate synthase (TS) and as anticancer agents. The in vitro anticancer activities of these compounds were evaluated against three cancer cell lines by the MTT method. Among all the designed compounds, compound 18 bearing a nitro substituent exhibited more potent in vitro anticancer activities with IC50 values of 0.7 ± 0.2, 30.0 ± 1.2, 18.3 ± 1.4 μM, respectively, which was superior to the positive control. In the further study, it was identified as the most potent inhibitor against two kinds of TS protein (for human TS and Escherichia coli TS, IC50 values: 0.62 and 0.47 μM, respectively) in the TS inhibition assay in vitro and the most potent antibacterial agents with MIC (minimum inhibitory concentrations) of 1.56-3.13 μg/mL against the tested four bacterial strains. Molecular docking and 3D-QSAR study supported that compound 18 can be selected as dual antitumor/antibacterial candidate in the future study.

Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents

A series of novel 1,3,4-oxadiazole derivatives (5a-5s) have been designed, synthesized and evaluated for their immunosuppressive activity. Most of these synthesized compounds were proved to have potent immunosuppressive activity and low toxicity. Among th

Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4] dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase

Two series of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives C1-C15 and D1-D15 have been synthesized and evaluated for their B-Raf inhibitory and anti-proliferation activities. Compound C14 ((3-(4-bromophenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methanone) showed the most potent biological activity against B-RafV600E (IC50 = 0.11 μM) and WM266.4 human melanoma cell line (GI50 = 0.58 μM), being comparable with the positive control Erlotinib and more potent than our previous best compound, while D10 ((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)(5-(3- fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone) performed the best in the D series (IC50 = 1.70 μM; GI50 = 1.45 μM). The docking simulation was performed to analyze the probable binding models and poses and the QSAR model was built for reasonable design of B-Raf inhibitors in future. The introduction of 2,3-dihydrobenzo[b][1,4]dioxin structure reinforced the combination of our compounds and the receptor, resulting in progress of bioactivity.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.